Skip to main content
HRES 343 112th Congress House

Expressing disapproval of the decision by the Supreme Court in Sorrell v. IMS Health Inc.

Introduced: July 8, 2011 Introduced by: Markey, Edward J. Democratic · Massachusetts See on congress.gov
Health First Amendment rightsHealth care costs and insuranceHealth information and medical recordsHealth personnel
More subjectsShow fewer subjects
Marketing and advertisingPrescription drugsRight of privacyState and local government operationsSupreme Court
Sign in to write a letter Sign in to watch
This resolution expired with the 112th Congress
It was not agreed to before the 112th Congress (2011–2012) adjourned, so it is no longer active. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Agreed to (House)
Aug 25, 2011
Referred to the Subcommittee on the Constitution.
Jul 15, 2011
Referred to the Subcommittee on Health.
Jul 8, 2011
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 8, 2011
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action August 25, 2011

Referred to the Subcommittee on the Constitution.

 Plain-English summary Congressional Research Service

Disapproves of the majority opinion in Sorrell v. IMS Health Inc., because it puts prescribers at risk of having their prescriber-identifying information sold without their knowledge or consent.

Expresses the belief of the House of Representatives that: (1) the Supreme Court incorrectly applied a heightened First Amendment standard of review to an instance of commercial regulation; (2) the negative impact on a pharmaceutical manufacturer's ability to market its products is outweighed by the interests of patient safety, doctor privacy, and health care costs; and (3) the states have the right to regulate the pharmaceutical industry based on what is best for the health and safety of their residents.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H. Res. 343: Expressing disapproval of the decision by the Supreme Court in Sorrell v. IMS Health Inc.. 112th Congress. Open America. https://openamerica.io/bill/112-HRES-343/
MLA
"H. Res. 343: Expressing disapproval of the decision by the Supreme Court in Sorrell v. IMS Health Inc.." 112th Congress, 2026, Open America, https://openamerica.io/bill/112-HRES-343/.
Bluebook (legal)
H. Res. 343, 112th Cong. (2026), https://openamerica.io/bill/112-HRES-343/.
Markdown link
[H. Res. 343: Expressing disapproval of the decision by the Supreme Court in Sorrell v. IMS Health Inc.](https://openamerica.io/bill/112-HRES-343/)
Report a problem